Management of disseminated intravascular coagulation: current insights on antithrombin and thrombomodulin treatments

References

• Singer M, Deutschman CS, Seymour CW, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016;315(8):801–810.
   PubMed Web of Science ®Google Scholar
• Levi M, Ten Cate H. Disseminated intravascular coagulation. N Engl J Med. 1999;341(8):586–592.
   PubMed Web of Science ®Google Scholar
• Rangel-Frausto MS, Pittet D, Costigan M, et al. The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study. JAMA. 1995;273(2):117–123.
   PubMed Web of Science ®Google Scholar
• Hayakawa M, Saito S, Uchino S, et al. Characteristics, treatments, and outcomes of severe sepsis of 3195 ICU-treated adult patients throughout Japan during 2011-2013. J Intensive Care. 2016;4:44.
   PubMed Web of Science ®Google Scholar
• Ogura H, Gando S, Saitoh D, et al. Epidemiology of severe sepsis in Japanese intensive care units: a prospective multicenter study. J Infect Chemother. 2014;20(3):157–162.
   PubMed Web of Science ®Google Scholar
• Matsuda N, Oda N, Aibiki M, et al. [2007 JSICM Sepsis 1st Registry: management of severe sepsis and septic shock in Japan]. J Jpn Soc Intensive Care Med. 2013;20:329–334. Japanese [with English abstract].
   Google Scholar
• Dellinger RP, Levy MM, Rhodes A, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med. 2013;41(2):580–637.
   PubMed Web of Science ®Google Scholar
• Dellinger RP, Levy MM, Rhodes A, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med. 2013;39(2):165–228.
   PubMed Web of Science ®Google Scholar
• Rhodes A, Evans LE, Alhazzani W, et al. Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock: 2016. Crit Care Med. 2017;45(3):486–552.
   PubMed Web of Science ®Google Scholar
• Rhodes A, Evans LE, Alhazzani W, et al. Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Med. 2017;43(3):304–377.
   PubMed Web of Science ®Google Scholar
• Murata A, Okamoto K, Mayumi T, Muramatsu K, Matsuda S. Recent change in treatment of disseminated intravascular coagulation in Japan: an epidemiological study based on a national administrative database. Clin Appl Thromb Hemost. 2016;22(1):21–27.
   PubMed Web of Science ®Google Scholar
• Beale R, Reinhart K, Brunkhorst FM, et al. Promoting Global Research Excellence in Severe Sepsis (PROGRESS): lessons from an international sepsis registry. Infection. 2009;37(3):222–232.
   PubMed Web of Science ®Google Scholar
• Warren BL, Eid A, Singer P, et al. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA. 2001;286(15):1869–1878.
   PubMed Web of Science ®Google Scholar
• Abraham E, Reinhart K, Opal S, et al. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA. 2003;290(2):238–247.
   PubMed Web of Science ®Google Scholar
• Ranieri VM, Thompson BT, Barie PS, et al. Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med. 2012;366(22):2055–2064.
   PubMed Web of Science ®Google Scholar
• Abraham E, Laterre PF, Garg R, et al. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med. 2005;353(13):1332–1341.
   PubMed Web of Science ®Google Scholar
• Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001;344(10):699–709.
   PubMed Web of Science ®Google Scholar
• Freeman BD, Zehnbauer BA, Buchman TG. A meta-analysis of controlled trials of anticoagulant therapies in patients with sepsis. Shock. 2003;20(1):5–9.
   PubMed Web of Science ®Google Scholar
• Kienast J, Juers M, Wiedermann CJ, et al. Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. J Thromb Haemost. 2006;4(1):90–97.
   PubMed Web of Science ®Google Scholar
• Dhainaut JF, Yan SB, Joyce DE, et al. Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation. J Thromb Haemost. 2004;2(11):1924–1933.
   PubMed Web of Science ®Google Scholar
• Umemura Y, Yamakawa K, Ogura H, et al. Efficacy and safety of anticoagulant therapy in three specific populations with sepsis: a meta-analysis of randomized controlled trials. J Thromb Haemost. 2016;14(3):518–530.
   PubMed Web of Science ®Google Scholar
• Roemisch J, Gray E, Hoffmann JN, et al. Antithrombin: a new look at the actions of a serine protease inhibitor. Blood Coagul Fibrinolysis. 2002;13(8):657–670.
   PubMed Web of Science ®Google Scholar
• Opal SM, Kessler CM, Roemisch J, et al. Antithrombin, heparin, and heparan sulfate. Crit Care Med. 2002;30(5 Suppl):S325–S331.
   PubMed Web of Science ®Google Scholar
• Aibiki M, Fukuoka N, Umakoshi K, et al. Serum albumin levels anticipate antithrombin III activities before and after antithrombin III agent in critical patients with disseminated intravascular coagulation. Shock. 2007;27(2):139–144.
   PubMed Web of Science ®Google Scholar
• Seitz R, Wolf M, Egbring R, et al. The disturbance of hemostasis in septic shock: role of neutrophil elastase and thrombin, effects of antithrombin III and plasma substitution. Eur J Haematol. 1989;43(1):22–28.
   PubMed Web of Science ®Google Scholar
• Sie P, Letrenne E, Caranobe C, et al. Factor II related antigen and antithrombin III levels as indicators of liver failure in consumption coagulopathy. Thromb Haemost. 1982;47(3):218–220.
   PubMed Web of Science ®Google Scholar
• Fourrier F, Chopin C, Goudemand J, et al. Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies. Chest. 1992;101(3):816–823.
   PubMed Web of Science ®Google Scholar
• Levi M, van der Poll T. The role of natural anticoagulants in the pathogenesis and management of systemic activation of coagulation and inflammation in critically ill patients. Semin Thromb Hemost. 2008;34(5):459–468.
   PubMed Web of Science ®Google Scholar
• Chappell D, Brettner F, Doerfler N, et al. Protection of glycocalyx decreases platelet adhesion after ischaemia/reperfusion: an animal study. Eur J Anaesthesiol. 2014;31(9):474–481.
   PubMed Web of Science ®Google Scholar
• Iba T, Saitoh D. Efficacy of antithrombin in preclinical and clinical applications for sepsis-associated disseminated intravascular coagulation. J Intensive Care. 2014;2(1):66.
   PubMedGoogle Scholar
• Iba T, Thachil J. Present and future of anticoagulant therapy using antithrombin and thrombomodulin for sepsis-associated disseminated intravascular coagulation: a perspective from Japan. Int J Hematol. 2016;103(3):253–261.
   PubMed Web of Science ®Google Scholar
• Inthorn D, Hoffmann JN, Hartl WH, et al. Antithrombin III supplementation in severe sepsis: beneficial effects on organ dysfunction. Shock. 1997;8(5):328–334.
   PubMed Web of Science ®Google Scholar
• Baudo F, Caimi TM, de Cataldo F, et al. Antithrombin III (ATIII) replacement therapy in patients with sepsis and/or postsurgical complications: a controlled double-blind, randomized, multicenter study. Intensive Care Med. 1998;24(4):336–342.
   PubMed Web of Science ®Google Scholar
• Eisele B, Lamy M, Thijs LG, et al. Antithrombin III in patients with severe sepsis. A randomized, placebo-controlled, double-blind multicenter trial plus a meta-analysis on all randomized, placebo-controlled, double-blind trials with antithrombin III in severe sepsis. Intensive Care Med. 1998;24(7):663–672.
   PubMed Web of Science ®Google Scholar
• Tagami T, Matsui H, Horiguchi H, et al. Antithrombin and mortality in severe pneumonia patients with sepsis-associated disseminated intravascular coagulation: an observational nationwide study. J Thromb Haemost. 2014;12(9):1470–1479.
   PubMed Web of Science ®Google Scholar
• Tagami T, Matsui H, Fushimi K, et al. Supplemental dose of antithrombin use in disseminated intravascular coagulation patients after abdominal sepsis. Thromb Haemost. 2015;114(3):537–545.
   PubMed Web of Science ®Google Scholar
• Hayakawa M, Kudo D, Saito S, et al. Antithrombin supplementation and mortality in sepsis-induced disseminated intravascular coagulation: a multicenter retrospective observational study. Shock. 2016;46(6):623–631.
   PubMed Web of Science ®Google Scholar
• Hayakawa M, Yamakawa K, Saito S, et al. Recombinant human soluble thrombomodulin and mortality in sepsis-induced disseminated intravascular coagulation. A multicentre retrospective study. Thromb Haemost. 2016;115(6):1157–1166.
   PubMed Web of Science ®Google Scholar
• Iba T, Saitoh D, Wada H, et al. Efficacy and bleeding risk of antithrombin supplementation in septic disseminated intravascular coagulation: a secondary survey. Crit Care. 2014;18(5):497.
   PubMed Web of Science ®Google Scholar
• Weiler H. Regulation of inflammation by the protein C system. Crit Care Med. 2010;38(2 Suppl):S18–S25.
   PubMed Web of Science ®Google Scholar
• Esmon CT, Esmon NL, Harris KW. Complex formation between thrombin and thrombomodulin inhibits both thrombin-catalyzed fibrin formation and factor V activation. J Biol Chem. 1982;257(14):7944–7947.
   PubMed Web of Science ®Google Scholar
• Aikawa N, Shimazaki S, Yamamoto Y, et al. Thrombomodulin alfa in the treatment of infectious patients complicated by disseminated intravascular coagulation: subanalysis from the phase 3 trial. Shock. 2011;35(4):349–354.
   PubMed Web of Science ®Google Scholar
• Saito H, Maruyama I, Shimazaki S, et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial. J Thromb Haemost. 2007;5(1):31–41.
   PubMed Web of Science ®Google Scholar
• Yamakawa K, Fujimi S, Mohri T, et al. Treatment effects of recombinant human soluble thrombomodulin in patients with severe sepsis: a historical control study. Crit Care. 2011;15(3):R123.
   PubMed Web of Science ®Google Scholar
• Yamakawa K, Ogura H, Fujimi S, et al. Recombinant human soluble thrombomodulin in sepsis-induced disseminated intravascular coagulation: a multicenter propensity score analysis. Intensive Care Med. 2013;39(4):644–652.
   PubMed Web of Science ®Google Scholar
• Vincent JL, Ramesh MK, Ernest D, et al. A randomized, double-blind, placebo-controlled, Phase 2b study to evaluate the safety and efficacy of recombinant human soluble thrombomodulin, ART-123, in patients with sepsis and suspected disseminated intravascular coagulation. Crit Care Med. 2013;41(9):2069–2079.
   PubMed Web of Science ®Google Scholar
• Yamakawa K, Aihara M, Ogura H, et al. Recombinant human soluble thrombomodulin in severe sepsis: a systematic review and meta-analysis. J Thromb Haemost. 2015;13(4):508–519.
   PubMed Web of Science ®Google Scholar
• Phase 3 safety and efficacy study of ART-123 in subjects with severe sepsis and coagulopathy. Available from: https://clinicaltrials.gov/show/NCT01598831. Accessed July 1, 2016.
   Google Scholar
• Gando S, Iba T, Eguchi Y, et al. A multicenter, prospective validation of disseminated intravascular coagulation diagnostic criteria for critically ill patients: comparing current criteria. Crit Care Med. 2006;34(3):625–631.
   PubMed Web of Science ®Google Scholar